BEIJING, January 1, 2025 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) is proud to announce that it has been officially recognized as a "Beijing Innovative Small and Medium-sized Enterprise (SME)" by the Beijing Municipal Bureau of Economy and Information Technology. This prestigious designation underscores Byongen’s robust R&D capabilities and its rapid progress in translating cutting-edge science into transformative gene therapy solutions.
The "Innovative SME" title is awarded to companies that demonstrate exceptional strength in core technical research, intellectual property accumulation, and overall development potential. For Byongen, this recognition serves as a validation of its proprietary DynEvoLib® AAV capsid discovery platform and its commitment to overcoming the delivery barriers of next-generation gene therapies.
"We are honored to receive this official recognition, which reflects the hard work of our scientific team and our steady growth within Beijing’s vibrant biotech ecosystem," said Gang Wang, Ph.D., Founder and CEO of Byongen Therapeutics. "As we move forward, this distinction reinforces our momentum in developing precise, safe, and highly efficient AAV vectors to address critical unmet medical needs globally."
This milestone marks another step in Byongen’s trajectory toward becoming a leader in the viral vector engineering space, further empowering the company to accelerate its pipeline development and clinical translation efforts.
About Byongen Therapeutics
Byongen Therapeutics is a biotechnology company focused on original innovation in AAV delivery technologies. The company aims to address core clinical delivery bottlenecks through capsid engineering. By leveraging its proprietary DynEvoLib® platform, Byongen integrates AI, rational design, and high-throughput directed evolution to develop next-generation AAV capsids. Byongen’s R&D focus targets the development of specialized capsids for neuromuscular and central nervous system (CNS) diseases.
京公网安备11011502040057号
